CLINICAL TRIAL SUMMARY

MDACC Study No:2005-0015 (clinicaltrials.gov NCT No: NCT00385788)
Title:Allogeneic stem cell transplantation followed by adoptive immunotherapy for patients with relapsed and refractory Hodgkin's Disease
Principal Investigator:Paolo Anderlini
Treatment Agent:Antithymocyte Globulin; Fludarabine; Gemcitabine; Melphalan
Study Status:Open
Study Description:The goal of this clinical research study is to learn if fludarabine, melphalan
and gemcitabine followed by transplantation of stem cells (blood-forming cells)
as well as immune cells (lymphocytes), collected from a matched related (i.e. a
sibling) or unrelated donor, or a mismatched related donor, can help to control
Hodgkin’s disease. The safety of the treatment will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Blood And Marrow Transplantation
Phase of Study:Phase II
Treatment Agents:Antithymocyte Globulin
Fludarabine
Gemcitabine
Melphalan
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:One 21-28 days hospitalization (uncomplicated course)
Supported By:N/A
Return Visit:Daily to once weekly from hospital discharge to day 100. Once a month until
day 180-360, then every 6-12 months thereafter.
Home Care:Intravenous fluids/electrolytes, growth factors, antibiotics, antifungals,
antivirals.


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Paolo Anderlini
Dept:Stem Cell Transplantation and Cellular Therapy
For Clinical Trial Enrollment:713-792-8750
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults